1. Home
  2. News
  3. Axol Bioscience Introduces Steve Rees as Scientific Advisory Board Member at SLAS 2016

Axol Bioscience Introduces Steve Rees as Scientific Advisory Board Member at SLAS 2016

Axol Bioscience Introduces Steve Rees as Scientific Advisory Board Member at SLAS 2016


The stem cell disease model specialists also showcase expanded range of primary and iPSC-derived cells for drug discovery

Cambridge, UK, 20 January 2016: Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB). Dr Rees will be attending the fifth annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA from 23-27 January 2016, where Axol will showcase the newest addition to its growing range of primary and induced pluripotent stem cell (iPSC)-derived cells for drug discovery through several poster presentations and an exhibitor tutorial.

Axol Announces Steve Rees as Scientific Advisory Board Member

Steve Rees is President of Screening Sciences and Sample Management, AstraZeneca, sits on the Board of Directors, European Laboratory Robotics Interest Group (ELRIG) and is a member of the Europe Council, SLAS. A renowned expert amongst the drug discovery community, Dr Rees will guide Axol in developing and validating products that are in line with current industry trends and aid the company in bringing cutting-edge solutions to its customers.

Dr Rees, SAB Member, Axol Bioscience commented, ‘SLAS is a very collaborative culture and of great value in terms of networking and learning best practice about state-of-the-art technologies in the field of drug discovery and laboratory automation from like-minded scientists. Dr Yichen Shi, CEO, Axol Bioscience said, ‘With Dr Rees as a member of Axol’s SAB, we look forward to collaborating on projects to develop solutions that could help us enhance our ability to discover drugs in future.’

Axol Expands Range of Primary and iPSC-Derived Cells

Axol who already offers a number of primary and iPSC-derived cells from healthy and patient donors, will be showcasing the latest addition to these ranges. This includes the launch of:

Assay-Ready Expanded (ARE) Hepatocytes Highly characterized and validated hepatocytes that are qualified for CYP induction, metabolism studies and micronucleus genotoxicity assays. Axol ARE Hepatocytes are available in large batch sizes, meaning they offer a reliable source of hepatocytes from the same donor for consistency from preliminary experiments to high-throughput screening. The Axol ARE range also comes complete with thawing and assay culture media for optimal revival, maintenance and viability of liver cells.

iPSC-Derived Astrocytes Mature astrocytes and progenitor cells derived from integration-free human iPSCs are ready-to-use, easy-to-differentiate and allow scientists to build physiologically relevant cellular models in vitro for neurotoxicity testing and drug screening.

Isogenic Central Nervous System (CNS) Disease-Specific Knockouts Axol has expanded its collection of isogenic CNS disease-specific neural stem cells to include Parkinson’s disease, amyotrophic lateral sclerosis (ALS), schizophrenia, autism and additional Alzheimer’s disease mutations. The extended range offers researchers a readily accessible source of knockout lines to investigate the functional effect of several genes implicated in dopaminergic neuron dysfunction.

Axol Stem Cell Experts Present at SLAS 2016

The Axol Exhibitor Tutorial will be held on 26 January 2016 from 2:00-2:45pm in Room 3. Dr Alfredo Cabrera, Scientist, Janssen Pharmaceutica will present ‘Modelling Alzheimer’s Disease: A High Throughput-Compatible Assay for Detecting TAU Aggregation Using iPSC-Derived Cortical Neurons’. Dr Cabrera will also present a poster (#5023) on this topic on 25 January 2016 from 1:00-3:00pm.

Dr Priyanka Dutta-Passecker, Business Development Manager, Axol Bioscience will present ‘Serum-free human iPSC-derived cardiomyocytes for contactless in vitro testing’ (poster #2097) on 25 January 2016 from 1:00-3:00pm and ‘Characterization and potential applications of human iPSC-derived neural stem cells’ (poster #2090) on 26 January 2016 from 1:00-3:00pm.

Axol invites all SLAS 2016 attendees wanting to discover more about how its range of human cell culture products and services can be used in drug discovery applications to visit booth #1655, exhibitor tutorial and poster presentation sessions.

Press enquiries

Dr Michelle Ricketts

Axol Bioscience

+44 1223 751051




About Axol Bioscience

Axol was co-founded by Jonathan Milner, PhD and Yichen Shi, PhD whose combined expertise and entrepreneurial spirit was the driving force behind the creation of Axol – where innovation, quality and customer service are key. Axol produces highly validated, human cells and critical reagents such as media and growth supplements. The Axol team is passionate about great science, delivering superb customer service and support and innovating future products to help customers advance their research faster. To find out more, visit axolbio.com

Axol Bioscience re-locate to Chesterford Research Park to facilitate future growth
Axol Bioscience Announces Chas Bountra as Scientific Advisory Board Member